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Objectives. Platelet monocyte aggregates (PMA) and monocyte chemoattractant protein-1 (MCP-1) play a significant
role in atherosclerotic disease but the effect of aspirin and their role in peripheral arterial disease (PAD) requires further
investigation. We have compared p-selectin, PMA and MCP-1 in patients with PAD treated with aspirin (75mgs daily),
with age matched controls not treated with aspirin.
Materials and methods. Using flow cytometry and ELISA, P-selectin, PMA and MCP-1 were compared in 3 popula-
tions; healthy controls (n¼ 12), intermittent claudication (n¼ 19) and critical limb ischaemia (CLI), (n¼ 10).
Results. P-selectin was significantly higher in CLI patients (3.48% positive) compared to the claudicants (1. 36% positive)
and the controls (1.76% positive). PMA levels were significantly higher for CLI population (44.5% positive) compared to
the claudicants (20.48% positive) and the controls (28.33% positive). MCP-1 levels expression was significantly higher for
the CLI patients (175.4 pg/mL) compared to the claudicants (76.1 pg/mL) and the controls (117.0 pg/mL).
Conclusion. Despite aspirin treatment CLI patients have higher platelet activation and MCP-1 expression than controls
and claudicants. With increasing severity of disease aspirin is unable to suppress markers of platelet activation and pro-
atherosclerotic chemokine expression which may represent another form of aspirin resistance.
Keywords: Platelets; Platelet monocyte aggregates; Monocyte chemoattractant protein 1; P-selectin; Peripheral arterial
disease; Aspirin.Introduction
Platelet monocyte aggregates (PMA) occur with vas-
cular inflammation and may represent a sensitive
marker of platelet activation. Risk factors for cardio-
vascular disease have been associated with increased
PMA expression. Smoking, diabetes and hyperlipi-
daemia have also been linked to elevated PMA
levels.1e3 The PMA is not unique to thrombo-embolic
conditions. Its role in sepsis has become increasingly
apparent with elevated levels seen in Systemic Inflam-
matory Response Syndrome.4 In addition PMA’s have
been associated with myeloproliferative disorders and
chronic venous disease.5e9 Numerous studies have
found associations between PMA’s and ischaemic
heart disease.10e14 However, the role of the PMA in
cerebral-vascular disease is not so well defined with
a single study showing elevated levels following
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with lower limb peripheral arterial disease (PAD) also
requires further investigation.
MCP-1 is an inflammatory chemokine released
from multiple cell types including endothelial cells,
smooth muscle cells and macrophages. MCP-1 re-
cruits mononuclear cells to sites of inflammation,
promoting endothelial adhesion and monocyte
extravasation through the endothelium.16 This chemo-
kine facilitates chronic inflammation, thrombosis,
angiogenesis, oxidative stress and vascular smooth
muscle cell proliferation and migration. Animal
models knockout for MCP-1, and its receptor CCR2,
show significant reduction in the atherosclerotic dis-
ease process.17,18 Other work has suggested that
MCP-1 may have a role in ischaemic reperfusion
injury.19,20 Reduced MCP-1 activity inhibits neo-
intimal hyperplasia and atheroma in the animal
model.21 In the presence of activated platelets, cul-
tured human umbilical endothelial cells show in-
crease MCP-1 expression.22 Similar effects have been
seen in aortic smooth muscle cells when incubated
with a-thrombin stimulated platelets.23 Despite theerved.
726 M. Cleanthis et al.recent growing interest in the role of MCP-1 in athero-
sclerosis, very little work has been published involving
PAD.24
PMA’s and inflammatory cytokines may represent
novel diagnostic tools and possible therapeutic targets
in the treatment and prevention of atherosclerosis.
The current study was performed to investigate the
expression of PMA, p-selectin and MCP-1 in PAD
patients treated with aspirin and to compare them
to healthy controls not treated with aspirin.
Materials and Methods
Patients
The study received local ethical approval and was
performed according to the declaration of Helsinki.
Informed consent was obtained from all patients prior
to their participation. Claudicants were recruited from
vascular outpatients and patients with critical limb
ischaemia (CLI) selected from the inpatient popula-
tion. Controls were selected from patients attending
hospital for day case hernia repair or minor local
anaesthetic procedures for non inflammatory and non-
infective conditions.
Inclusion and exclusion criteria
Patients aged between 40 and 85 years were included.
Subjects were included into one of three populations;
proven PAD (intermittent claudication with ABPI<0.9
and angiography or duplex proven lower limb dis-
ease), proven PAD with CLI (rest pain, ABPI 0.5, 
ulceration and angiography or duplex proven
lower limb disease), age matched controls (patients at-
tending for day case surgery with no lower limb
symptoms, ABPI 1.0, no known PVD or IHD). All
PAD patients were already on aspirin treatment
(75mgs once daily) prior to recruitment. Exclusion
criteria included chronic renal failure, diabetes
mellitus, malignancy, current infectious process or
gangrene, platelet disorders or platelet count <150
or >450 109/L, concurrent treatment with steroids,
anticoagulants or non-steroidal anti inflammatory
agents other than aspirin.
Blood collection
All blood sampling was completed before midday.
Venous blood was taken from the anticubital fossa
without tourniquet pressure using a 19G needle. The
first 5mls was discarded before collection into vacu-
tainers containing 1/10 volume of 3.8% sodium citrateEur J Vasc Endovasc Surg Vol 33, June 2007for flow cytometry and MCP1 assays. Plasma was iso-
lated from blood by centrifuge for 10 minutes at
1000 g, and stored at 80 C until assayed.
Flow cytometry
A whole blood two-colour staining technique was
used to quantify P-selectin as previously described.25,26
Anti-CD61 antibody, conjugated to a peridinin
chlorophyll protein (BD Biosciences, Oxford, UK),
was used to identify the platelet population. Anti-
CD62P antibody, conjugated to R-phytocoerythrin
(BD Biosciences, Oxford, UK), was used to quantify
platelet surface expression of P-selectin. Isotypic con-
trol samples were run in parallel (Y1, BD Biosciences,
Oxford, UK). 15000 platelet events were collected and
the results expressed as percentage cells positive for
Anti-CD62P antibody. PMA estimation was performed
as previously described.25,26 Anti-CD45 antibody
conjugated to peridinin chlorophyll (BD Biosciences,
Oxford, UK) was used as a pan-leukocytic marker.
Anti-CD14 antibody conjugated to R-phytocoerythrin
(Dako, UK) was used to identify the monocyte popula-
tion from other leukocyte subpopulations. Platelet
monocyte aggregates were measured as the percentage
of the monocyte population expressing the platelet
specific marker GpIIb/IIIa, quantified with fluorescein
isothiocyanate conjugated anti-CD61 antibody (Dako,
UK). Isotypic control samples were run in parallel
(IgG1, Dako, UK). 30,000 events were collected and the
results expressed as the percentage cells (monocytes)
positive for anti-CD61 antibody.
Monocyte chemoattractant protein-1 ELISA
MCP-1 was measured by ELISA using a commercially
available kit (R&D systems (Oxon, UK). The assay
procedure was fully automated (Best 2000, Biokit Elisa
systems, Barcelona, Spain) and performed according
to the manufacturers instructions.
Statistical analysis
Data was analysed using Minitab (release 13.1). Devia-
tions from Gaussian distribution were assessed using
the Anderson-darlington test. A Mann-Whitney test
was used for inter-group analysis.
Results
12 normal controls, 19 patients with PAD and 10 pa-
tients with CLI were recruited. The characteristics,
PAD risk factors and medication are summarised in
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were analysed to assess any significant difference in
age and no significant difference was identified
(p> 0.05, Mann-Whitney U test). There were signifi-
cantly more males in the PAD and CLI groups
(p< 0.05, Chi2). 2 of the CLI patients had leg ulcers.
All patients with CLI were identified to have signifi-
cant infra-inguinal disease. Half of this group also
had evidence of supra-inguinal disease but confined
to the iliac arteries. In the PAD group 11 of the patients
had isolated infra-inguinal occlusive disease, 2 had
occlusive diseases isolated to the supra-inguinal
region and 6 had combined infra and supra-inguinal
disease.
P-selectin (Fig. 1)
The median percentage positive cells expressing P-
selectin was significantly higher in the population
with CLI (3.48; IQR 1.9e9.07) compared to the claudi-
cants (1.36; IQR 0.7e2.65: p¼ 0.011) and the controls
(1.76; IQR 1.38e2.19: p¼ 0.025). Despite the claudicant
population exhibiting a lower median value com-
pared to the control population. The difference was
not statistically significant (p¼ 0.53).
PMA (Fig. 2)
The median percentage positive cells was higher for
the population with CLI (44.5; IQR 30.83e80.68)
Table 1. Baseline characteristics claudicants, CLI and controls
Age Matched
Controls
n¼ 12
Claudicants
n¼ 19
CLI n¼ 10
Age, years (Range) 66.5 (49e82) 64 (53e81) 68.5 (56e81)
Gender (M/F) 6/6 16/3 10/1
Ankle brachial pressure
index, (Range)
1.0 (1.0e1.2) 0.6 (0.5e0.8) 0.4 (0e0.5)
Risk factors
Smoking, n (%) 0 (0) 10 (53) 5 (50)
Hypercholesterolaemia,
n (%)
2 (17) 11 (58) 9 (90)
Hypertension, n (%) 3 (25) 9 (47) 5 (50)
Ischaemic Heart
disease, n (%)
0 (0) 5 (26) 5 (50)
Medications
b-blockers, n (%) 0 (0) 3 (16) 5 (50)
Calcium channel
blockers, n (%)
3 (25) 6 (32) 3 (30)
Statins, n (%) 1 (8) 9 (47) 9 (90)
Ace inhibitors, n (%) 0 (0) 4 (21) 5 (50)
Diuretics, n (%) 2 (17) 5 (26) 4 (40)
Nitrates, n (%) 0 (0) 2 (11) 3 (30)
Aspirin 0 (0) 19 (100) 10 (100)compared to the claudicant population (20.48; IQR
17.34e28.59) and the control population (28.33; IQR
20.63e35.93). The CLI population were significantly
higher than the claudicant population (p¼ 0.004)
and the control population (p¼ 0.036). There was no
statistically significant difference between the control
and claudicant populations (p¼ 0.103).
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Fig. 1. Platelet p-selectin expression in claudicants, CLI
and age matched controls. The box extends from the 25th
percentile to the 75th percentile, with a horizontal line to
represent the median. The whiskers show the highest and
lowest values. The population with critical ischaemia ex-
pressed P-selectin at a level significantly higher than the
claudicants or age matched ‘normal’ controls (*p< 0.05,
Mann-Whitney test).
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Fig. 2. PMA expression in claudicants, CLI and age
matched controls. The box extends from the 25th percentile
to the 75th percentile, with a horizontal line to represent the
median. The whiskers show the highest and lowest values.
The percentage positive cells was significantly higher in
the population with critical ischaemia (*p< 0.05, **p< 0.01,
Mann-Whitney Test).Eur J Vasc Endovasc Surg Vol 33, June 2007
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The median value for MCP-1 expression was maximal
for the critical ischaemic population (175.4 pg/mL;
IQR 156.4e255.2). The control population (117 pg/
mL; IQR 81.91e132.9) showed higher median values
than the claudicant population (76.1 pg/mL; IQR
72.04e85.38). The CLI population was significantly
higher than the claudicant (p< 0.0001) and the control
population (p¼ 0.0005). The difference between the
claudicant and control populations was also statisti-
cally significant (p¼ 0.0013).
Discussion
Although platelet hyperactivity has been previously
documented in PAD, this is the first study to compare
the expression of MCP-1, PMA and p-selectin
amongst these populations.27,28
In this study platelet P-selectin was seen to be
elevated in patients with CLI, despite treatment
with aspirin. In the claudicant population treated
with aspirin, the expression was comparable to age
matched controls not treated with aspirin. The pattern
of platelet monocyte aggregate expression mirrored
that of p-selectin with the highest levels being seen
in the population of CLI and the claudicants display-
ing levels comparable to age matched controls.
P-selectin is known to be important in the PMA inter-
action and hence both tests yielding comparable re-
sults adds strength to this finding. However, these
findings suggest that aspirin may offer some benefit
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Fig. 3. MCP-1 expression in claudicants, CLI and age
matched controls. The box extends from the 25th percentile
to the 75th percentile, with a horizontal line to represent the
median. The whiskers show the highest and lowest values
(*p< 0.01, **p< 0.001, ***p< 0.0001 Mann-Whitney test).Eur J Vasc Endovasc Surg Vol 33, June 2007in preventing platelet monocyte aggregate formation,
possibly via inhibition of p-selectin in the claudicant
population. In more advanced PAD the expression
of p-selectin may not be so well suppressed and hence
PMA expression is elevated. The effect of aspirin
on PMA requires further study. Although platelet-
leukocyte aggregates have not been shown to be
suppressed by aspirin a single study in CVA patients
suggests that PMA expression is reduced in aspirin
treated patients.29,30
The expression of P-selectin did not differ signifi-
cantly between claudicants and controls which is
comparable to previously published results.28
The expression of MCP-1 was significantly higher
in the CLI population but surprisingly lower in the
claudicant population. Although MCP-1 levels have
been studied in the context of CAD, only three studies
have compared this chemokine in PAD and non PAD
controls, and all showed elevated levels in PAD.24,31,32
None of these studies fully define the proportion of
their population treated with aspirin and contained
populations with varying severity of lower limb
PAD. In our study the PAD population is separated
into claudicants and CLI and both PAD populations
were treated with aspirin. Furthermore, the use of sta-
tin therapy is less clearly defined in other published
work which may offer some explanation to the differ-
ences seen between this study and other published
work.24
The effect of hyperlipidaemia and statin therapy on
MCP-1 expression has been previously published.33 A
greater proportion of the CLI population had a history
of hypercholesterolaemia compared to the PAD
group. However, treatment with statin therapy was
also greater in this population and hence it is unlikely
that the MCP-1 levels can be attributed to the inci-
dence of hypercholesterolaemia alone. The incidence
of smoking was also greater in the population with
CLI. This may offer some explanation towards the
elevated PMA levels seen in this group.
The action of aspirin is not limited to the platelet. It
has been shown to alter the expression of chemokines
involved in atherosclerosis. For example the endothe-
lial expression of MCP-1 is suppressed by aspirin in
the animal model.34,35 Measurement of aspirin resis-
tance has always focused on its antiplatelet effects
but no work has described resistance in terms of its
other actions. In this study as well as elevated platelet
markers in the CLI population we have shown sig-
nificantly elevated MCP-1 and its relevance needs
further investigation. MCP-1 has been linked to
atherosclerotic disease and atherosclerotic risk factors
and hence the high levels seen with advanced lower
limb PAD are to be expected.36 However we would
729PMA & MCP1 in PAD Patients Treated with Aspirinhave expected the intermittent claudication group to
also show high levels compared to the control group,
unless aspirin was able to significantly suppress the
expression of MCP-1.
This study suggests that patients with CLI have
greater platelet activation than controls and claudi-
cants and is in agreement with other studies using
different methods to assess platelet activation. Fur-
thermore, aspirin is able to suppress some of the
markers of platelet activation but with increasing
severity of disease its actions are overwhelmed with
evidence of increasing platelet activation and elevated
levels of the pro-atherosclerotic chemokine MCP-1.
Whether this is a result of increase atherosclerotic dis-
ease load or a greater incidence of atherosclerotic risk
factors cannot be concluded from this study. How-
ever, the results provide an argument for additional
antiplatelet agents in patients with CLI and further
work is required to assess the potential benefits of
both alternative and combination antiplatetlet
therapy.
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